(STE) STERIS - Overview

Sector: HealthcareIndustry: Medical Devices | Exchange NYSE (USA) | Currency USD | Market Cap: 21.762m | Total Return -2.2% in 12m

Stock Sterilization, Disinfection, Surgical Equipment, Contract Services
Total Rating 52
Risk 92
Buy Signal -1.18
Medical Devices -6.0
Health Care Equipment -2.9
Market Cap: 21,762m
Avg Trading Vol: 200M USD
ATR: 2.71%
Peers RS (IBD): 44.3
Risk 5d forecast
Volatility23.3%
Rel. Tail Risk-5.66%
Reward TTM
Sharpe Ratio-0.09
Alpha-8.99
Character TTM
Beta0.477
Beta Downside0.400
Drawdowns 3y
Max DD20.76%
CAGR/Max DD0.28
EPS (Earnings per Share) EPS (Earnings per Share) of STE over the last years for every Quarter: "2021-03": 1.63, "2021-06": 1.76, "2021-09": 1.99, "2021-12": 2.12, "2022-03": 2.04, "2022-06": 1.9, "2022-09": 1.99, "2022-12": 2.02, "2023-03": 2.3, "2023-06": 2, "2023-09": 2.03, "2023-12": 2.22, "2024-03": 2.58, "2024-06": 2.14, "2024-09": 2.14, "2024-12": 2.32, "2025-03": 2.74, "2025-06": 2.34, "2025-09": 2.47, "2025-12": 2.53,
EPS CAGR: 5.91%
EPS Trend: 78.2%
Last SUE: 0.00
Qual. Beats: 0
Revenue Revenue of STE over the last years for every Quarter: 2021-03: 873.531, 2021-06: 968.422, 2021-09: 1196.985, 2021-12: 1208.971, 2022-03: 1210.686, 2022-06: 1156.491, 2022-09: 1200.517, 2022-12: 1215.994, 2023-03: 1384.837, 2023-06: 1183.386, 2023-09: 1238.204, 2023-12: 1297.724, 2024-03: 1116.154, 2024-06: 1279.5, 2024-09: 1328.912, 2024-12: 1370.57, 2025-03: 1480.531, 2025-06: 1391.1, 2025-09: 1460.3, 2025-12: 1496.1,
Rev. CAGR: 5.81%
Rev. Trend: 76.6%
Last SUE: 0.13
Qual. Beats: 0
Description: STE STERIS March 02, 2026

STERIS plc (NYSE: STE) is a global provider of infection-prevention solutions, organized into three core segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment supplies cleaning chemistries, endoscope reprocessing systems, and a full suite of sterile-processing equipment and services for hospitals. AST offers contract sterilization and testing for medical-device and pharmaceutical makers, together with integrated sterilization hardware. The Life Sciences segment manufactures consumables such as pharmaceutical detergents, clean-room disinfectants, vapor-phase hydrogen-peroxide systems, and high-purity water generators, plus related installation and maintenance services.

In FY 2025 STE reported revenue of $4.2 billion, up 7 % year-over-year, driven by strong demand for infection-control products amid heightened antimicrobial-resistance concerns and expanding hospital procedural volumes. Operating margin improved to 13 % and diluted EPS reached $3.45, while free cash flow of $450 million supported a $1.1 billion backlog of capital-equipment orders. Sector-wide, U.S. healthcare capital expenditures are projected to grow 4-5 % annually through 2028, and the pharmaceutical contract-manufacturing market is expanding at ~6 % CAGR, both bolstering STE’s growth tailwinds.

For a deeper dive, you may want to explore ValueRay’s analyst notes.

Headlines to Watch Out For
  • Healthcare equipment sales and service contracts drive revenue
  • Contract sterilization demand from medical device manufacturers
  • Life Sciences consumables and equipment sales grow
  • Regulatory changes impact infection prevention product demand
  • Hospital capital expenditure trends influence equipment sales
Piotroski VR‑10 (Strict, 0-10) 8.5
Net Income: 707.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.15 > 1.0
NWC/Revenue: 23.40% < 20% (prev 19.76%; Δ 3.64% < -1%)
CFO/TA 0.12 > 3% & CFO 1.27b > Net Income 707.8m
Net Debt (1.63b) to EBITDA (1.36b): 1.20 < 3
Current Ratio: 2.48 > 1.5 & < 3
Outstanding Shares: last quarter (98.8m) vs 12m ago -0.14% < -2%
Gross Margin: 44.11% > 18% (prev 0.43%; Δ 4.37k% > 0.5%)
Asset Turnover: 56.58% > 50% (prev 50.91%; Δ 5.67% > 0%)
Interest Coverage Ratio: 11.64 > 6 (EBITDA TTM 1.36b / Interest Expense TTM 62.7m)
Altman Z'' 4.39
A: 0.13 (Total Current Assets 2.29b - Total Current Liabilities 922.3m) / Total Assets 10.59b
B: 0.27 (Retained Earnings 2.86b / Total Assets 10.59b)
C: 0.07 (EBIT TTM 730.2m / Avg Total Assets 10.30b)
D: 2.09 (Book Value of Equity 7.15b / Total Liabilities 3.42b)
Altman-Z'' Score: 4.39 = AA
Beneish M -3.07
DSRI: 0.95 (Receivables 990.6m/915.2m, Revenue 5.83b/5.10b)
GMI: 0.98 (GM 44.11% / 43.38%)
AQI: 0.94 (AQ_t 0.57 / AQ_t-1 0.60)
SGI: 1.14 (Revenue 5.83b / 5.10b)
TATA: -0.05 (NI 707.8m - CFO 1.27b) / TA 10.59b)
Beneish M-Score: -3.07 (Cap -4..+1) = AA
What is the price of STE shares? As of March 30, 2026, the stock is trading at USD 219.40 with a total of 726,865 shares traded.
Over the past week, the price has changed by -0.72%, over one month by -13.06%, over three months by -14.15% and over the past year by -2.23%.
Is STE a buy, sell or hold? STERIS has received a consensus analysts rating of 3.80. Therefor, it is recommend to hold STE.
  • StrongBuy: 3
  • Buy: 2
  • Hold: 5
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the STE price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 279.3 27.3%
Analysts Target Price 279.3 27.3%
STE Fundamental Data Overview March 26, 2026
P/E Trailing = 30.8816
P/E Forward = 20.1613
P/S = 3.7341
P/B = 3.0162
P/EG = 1.6806
Revenue TTM = 5.83b USD
EBIT TTM = 730.2m USD
EBITDA TTM = 1.36b USD
Long Term Debt = 1.90b USD (from longTermDebt, last quarter)
Short Term Debt = 34.4m USD (from shortTermDebt, last quarter)
Debt = 2.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.63b USD (from netDebt column, last quarter)
Enterprise Value = 23.39b USD (21.76b + Debt 2.05b - CCE 423.7m)
Interest Coverage Ratio = 11.64 (Ebit TTM 730.2m / Interest Expense TTM 62.7m)
EV/FCF = 25.51x (Enterprise Value 23.39b / FCF TTM 917.1m)
FCF Yield = 3.92% (FCF TTM 917.1m / Enterprise Value 23.39b)
FCF Margin = 15.74% (FCF TTM 917.1m / Revenue TTM 5.83b)
Net Margin = 12.14% (Net Income TTM 707.8m / Revenue TTM 5.83b)
Gross Margin = 44.11% ((Revenue TTM 5.83b - Cost of Revenue TTM 3.26b) / Revenue TTM)
Gross Margin QoQ = 43.81% (prev 44.23%)
Tobins Q-Ratio = 2.21 (Enterprise Value 23.39b / Total Assets 10.59b)
Interest Expense / Debt = 0.72% (Interest Expense 14.8m / Debt 2.05b)
Taxrate = 24.63% (63.5m / 257.8m)
NOPAT = 550.4m (EBIT 730.2m * (1 - 24.63%))
Current Ratio = 2.48 (Total Current Assets 2.29b / Total Current Liabilities 922.3m)
Debt / Equity = 0.29 (Debt 2.05b / totalStockholderEquity, last quarter 7.17b)
Debt / EBITDA = 1.20 (Net Debt 1.63b / EBITDA 1.36b)
Debt / FCF = 1.78 (Net Debt 1.63b / FCF TTM 917.1m)
Total Stockholder Equity = 6.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.87% (Net Income 707.8m / Total Assets 10.59b)
RoE = 10.21% (Net Income TTM 707.8m / Total Stockholder Equity 6.93b)
RoCE = 8.27% (EBIT 730.2m / Capital Employed (Equity 6.93b + L.T.Debt 1.90b))
RoIC = 6.21% (NOPAT 550.4m / Invested Capital 8.87b)
WACC = 7.05% (E(21.76b)/V(23.82b) * Re(7.66%) + D(2.05b)/V(23.82b) * Rd(0.72%) * (1-Tc(0.25)))
Discount Rate = 7.66% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -0.28%
[DCF] Terminal Value 84.77% ; FCFF base≈850.8m ; Y1≈1.05b ; Y5≈1.79b
[DCF] Fair Price = 373.5 (EV 38.26b - Net Debt 1.63b = Equity 36.63b / Shares 98.1m; r=7.05% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 78.20 | EPS CAGR: 5.91% | SUE: 0.0 | # QB: 0
Revenue Correlation: 76.65 | Revenue CAGR: 5.81% | SUE: 0.13 | # QB: 0
EPS next Quarter (2026-06-30): EPS=2.49 | Chg7d=-0.021 | Chg30d=-0.021 | Revisions Net=-2 | Analysts=6
EPS next Year (2027-03-31): EPS=11.08 | Chg7d=-0.019 | Chg30d=-0.019 | Revisions Net=-3 | Growth EPS=+8.6% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: -0.33 (2 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.7% (Discount Rate 7.9% - Earnings Yield 3.2%)
[Growth] Growth Spread = +2.0% (Analyst 6.7% - Implied 4.7%)
Additional Sources for STE Stock Fund Manager Positions: Dataroma · Stockcircle